"From a pricing standpoint, we have to price our medicines in a way that's reflective of the value they create. And we have to be comfortable with the fact that if our medicines aren't creating enough value for society, then people aren't gonna want to pay for them."

Novartis' Vas Narasimhan sits with LinkedIn Editor-in-Chief Daniel Roth to talk about his first 100 days as CEO, his views on the industry, and his favorite leadership book. What's next for a pharma industry undergoing transformation? Join the conversation using the hashtags #Pharma #Novartis

свернуть